Patents by Inventor Hongkui Zeng
Hongkui Zeng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240018543Abstract: Artificial expression constructs for modulating gene expression in targeted central nervous system cell types are described. The artificial expression constructs can be used to express synthetic genes or modify gene expression in chandelier cells. Chandelier cells are a subtype of GABAergic interneurons that that have been implicated in disorders such as epilepsy and schizophrenia.Type: ApplicationFiled: November 10, 2021Publication date: January 18, 2024Applicant: Allen InstituteInventors: Tanya Daigle, Lucas T. Graybuck, Brian Edward Kalmbach, Edward Sebastian Lein, John K. Mich, Boaz P. Levi, Adriana Estela Sedeño Cortés, Bosiljka Tasic, Jonathan Ting, Hongkui Zeng
-
Publication number: 20230302158Abstract: Artificial expression constructs for modulating gene expression in striatal neurons are described. The artificial expression constructs can be used to express heterologous genes in striatal neurons including in striatal medium spiny neuron-pan, striatal medium spiny neuron-indirect pathway, striatal medium spiny neuron-direct pathway, striatal interneuron-cholinergic, and Drd3+ medium spiny neurons in olfactory tubercle. The artificial expression constructs can be used for many purposes, including to research and treat movement disorders such as Parkinson's disease and Huntington's disease.Type: ApplicationFiled: August 13, 2021Publication date: September 28, 2023Applicant: Allen InstituteInventors: Tanya Daigle, Edward Sebastian Lein, Boaz P. Levi, John K. Mich, Bosiljka Tasic, Jonathan Ting, Hongkui Zeng
-
Publication number: 20230212608Abstract: Artificial expression constructs for selectively modulating gene expression in selected central nervous system cell types are described. The artificial expression constructs can be used to selectively express synthetic genes or modify gene expression in inhibitory neocortical GABAergic neurons including somatostatin GABAergic neurons, parvalbumin GABAergic neurons, vasointestinal peptide GABAergic neurons, Lamp5 GABAergic neurons, and in some instances astrocytes.Type: ApplicationFiled: June 4, 2021Publication date: July 6, 2023Applicant: Allen InstituteInventors: Tanya Daigle, Lucas T. Graybuck, Edward Sebastian Lein, Boaz P. Levi, John K. Mich, Adriana Estela Sedeño Cortés, Bosiljka Tasic, Jonathan Ting, Miranda Walker, Hongkui Zeng
-
Publication number: 20230159952Abstract: Artificial expression constructs for selectively modulating gene expression in selected central nervous system cell types are described. Particularly, the artificial expression constructs can be used to selectively express synthetic genes and/or modify gene expression in neocortical glutamatergic layer 5 neurons, such as glutamatergic layer 5 extratelencephalic-projecting (L5 ET) neurons.Type: ApplicationFiled: April 21, 2021Publication date: May 25, 2023Applicant: ALLEN INSTITUTEInventors: Tanya Daigle, Lucas T. Graybuck, Brian Edward Kalmbach, Edward Sebastian Lein, Boaz P. Levi, John K. Mich, Adriana Estela Sedeño Cortés, Bosiljka Tasic, Jonathan Ting, Hongkui Zeng
-
Publication number: 20230117172Abstract: Artificial expression constructs for selectively modulating gene expression in selected central nervous system cell types are described. The artificial expression constructs can be used to selectively express synthetic genes or modify gene expression in astrocytes, oligodendrocytes, microglia, pericytes, SMC, or endothelial cells.Type: ApplicationFiled: March 26, 2021Publication date: April 20, 2023Applicant: ALLEN INSTITUTEInventors: Jonathan Ting, Bosiljka Tasic, Boaz P. Levi, Tanya Daigle, Lucas T. Graybuck, Edward Sebastian Lein, John K. Mich, Adriana Estela Sedeño Cortés, Hongkui Zeng
-
Publication number: 20220249703Abstract: Artificial expression constructs for selectively modulating gene expression in selected central nervous system cell types are described. The artificial expression constructs can be used to selectively express synthetic genes or modify gene expression in GABAergic neurons generally; and/or GABAergic neuron cell types such as lysosomal associated membrane protein 5 (Lamp5) neurons; vasoactive intestinal polypeptide-expressing (Vip) neurons; somatostatin (Sst) neurons; and/or parvalbumin (Pvalb) neuron cell types. Certain artificial expression constructs additionally drive selective gene expression in Layer 4 and/or layer 5 intratelencephalic (IT) neurons, deep cerebellar nuclear neurons or cerebellar Purkinje cells.Type: ApplicationFiled: February 14, 2020Publication date: August 11, 2022Applicant: Allen InstituteInventors: Jonathan Ting, Boaz P. Levi, Bosiljka Tasic, John K. Mich, Erik Hess, Edward Sebastian Lein, Lucas T. Graybuck, Tanya Daigle, Hongkui Zeng
-
Publication number: 20210395780Abstract: Artificial expression constructs for selectively modulating gene expression in selected central nervous system cell types are described. The artificial expression constructs can be used to selectively express synthetic genes or modify gene expression in excitatory cortical neurons, such as primarily within cortical layers 2/3, 4, 5, and 6 and including those with extratelencephalic (ET) projections, intratelencephalic (IT) projections, and pyramidal tract (PT) projections, among others.Type: ApplicationFiled: November 5, 2019Publication date: December 23, 2021Applicant: Allen InstituteInventors: Lucas T. Graybuck, Bosiljka Tasic, Tanya Daigle, Jonathan Ting, Hongkui Zeng, Brian Edward Kalmbach, John K. Mich, Erik Hess, Edward Sebastian Lein, Boaz P. Levi
-
Publication number: 20190183824Abstract: A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.Type: ApplicationFiled: December 6, 2018Publication date: June 20, 2019Inventors: John E. Bergmann, Neil S. Cutshall, Gregory A. Demopulos, Vincent A. Florio, George A. Gaitanaris, Patrick Gray, John Hohmann, Rene Onrust, Hongkui Zeng
-
Patent number: 10292374Abstract: The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels.Type: GrantFiled: November 10, 2016Date of Patent: May 21, 2019Assignee: Omeros CorporationInventors: George A. Gaitanaris, John E. Bergmann, Alexander Gragerov, John Hohmann, Fusheng Li, Linda Madisen, Kellie L. McIlwain, Maria N. Pavlova, Demetri Vassilatis, Hongkui Zeng
-
Publication number: 20170188555Abstract: The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels.Type: ApplicationFiled: November 10, 2016Publication date: July 6, 2017Inventors: George A. Gaitanaris, John E. Bergmann, Alexander Gragerov, John Hohmann, Fusheng Li, Linda Madisen, Kellie L. McIlwain, Maria N. Pavlova, Demetri Vassilatis, Hongkui Zeng
-
Publication number: 20160282365Abstract: The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels.Type: ApplicationFiled: January 27, 2016Publication date: September 29, 2016Inventors: George A. Gaitanaris, John E. Bergmann, Alexander Gragerov, John Hohmann, Fusheng Li, Linda Madisen, Kellie L. McIlwain, Maria N. Pavlova, Demetri Vassilatis, Hongkui Zeng
-
Publication number: 20160219845Abstract: The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels.Type: ApplicationFiled: February 27, 2015Publication date: August 4, 2016Inventors: George A. Gaitanaris, John E. Bergmann, Alexander Gragerov, John Hohmann, Fusheng Li, Linda Madisen, Kellie L. McIlwain, Maria N. Pavlova, Demetri Vassilatis, Hongkui Zeng
-
Publication number: 20160015715Abstract: A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.Type: ApplicationFiled: July 22, 2015Publication date: January 21, 2016Inventors: John E. Bergmann, Neil S. Cutshall, Gregory A. Demopulos, Vincent A. Florio, George A. Gaitanaris, Patrick Gray, John Hohmann, Rene Onrust, Hongkui Zeng
-
Patent number: 9119822Abstract: A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.Type: GrantFiled: December 13, 2013Date of Patent: September 1, 2015Assignee: Omeros CorporationInventors: John E. Bergmann, Neil S. Cutshall, Gregory A. Demopulos, Vincent A. Florio, George A. Gaitanaris, Patrick Gray, John Hohmann, Rene Onrust, Hongkui Zeng
-
Patent number: 8999654Abstract: The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels.Type: GrantFiled: October 29, 2010Date of Patent: April 7, 2015Assignee: Omeros CorporationInventors: George A. Gaitanaris, John E. Bergmann, Alexander Gragerov, John Hohmann, Fusheng Li, Linda Madisen, Kellie L. McIlwain, Maria N. Pavlova, Demetri Vassilatis, Hongkui Zeng
-
Publication number: 20140179717Abstract: A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.Type: ApplicationFiled: December 13, 2013Publication date: June 26, 2014Applicant: OMEROS CORPORATIONInventors: John E. Bergmann, Neil S. Cutshall, Gregory A. Demopulos, Vincent A. Florio, George A. Gaitanaris, Patrick Gray, John Hohmann, Rene Onrust, Hongkui Zeng
-
Patent number: 8637528Abstract: A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.Type: GrantFiled: May 4, 2009Date of Patent: January 28, 2014Assignee: Omeros CorporationInventors: John E Bergmann, Neil S Cutshall, Gregory A Demopulos, Vincent A Florio, George Gaitanaris, Patrick Gray, John Hohmann, Rene Onrust, Hongkui Zeng
-
Publication number: 20130247233Abstract: The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels.Type: ApplicationFiled: March 12, 2013Publication date: September 19, 2013Applicant: OMEROS CORPORATIONInventors: George A. Gaitanaris, John E. Bergmann, Alexander Gragerov, John Hohmann, Fusheng Li, Linda Madisen, Kellie L. McIlwain, Maria N. Pavlova, Demetri Vassilatis, Hongkui Zeng
-
Patent number: 8278327Abstract: Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: wherein m, n, p, x, R, R1, R2, R3, R4, R5, A and B, are defined herein, including pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.Type: GrantFiled: August 2, 2010Date of Patent: October 2, 2012Assignee: Omeros CorporationInventors: John E. Bergmann, Neil S. Cutshall, Rene Onrust, Hongkui Zeng, Jennifer Lynn Gage, Derek Johnston, Sándor Cseh, László Ürögdi, Ákos Papp
-
Publication number: 20110214189Abstract: The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels.Type: ApplicationFiled: October 29, 2010Publication date: September 1, 2011Applicant: OMEROS CORPORATIONInventors: GEORGE A. GAITANARIS, JOHN E. BERGMANN, ALEXANDER GRAGEROV, JOHN HOHMANN, FUSHENG LI, LINDA MADISEN, KELLIE L. MCILWAIN, MARIA N. PAVLOVA, DEMETRI VASSILATIS, HONGKUI ZENG